{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"15.8","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11.\n\n\\>\n\n\\> Aurora A kinase inhibitor MLN8237: Given orally\n\n\\>\n\n\\> bortezomib: Given IV","id":"OG000","title":"All Patients"}],"paramType":"MEDIAN","populationDescription":"All patients that received treatment were evaluated.","reportingStatus":"POSTED","timeFrame":"Every 28 day cycle(up to 10 cycles) then follow-up for up to 2 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}